These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 22236920)

  • 1. Rise in rifampicin-monoresistant tuberculosis in Western Cape, South Africa.
    Mukinda FK; Theron D; van der Spuy GD; Jacobson KR; Roscher M; Streicher EM; Musekiwa A; Coetzee GJ; Victor TC; Marais BJ; Nachega JB; Warren RM; Schaaf HS
    Int J Tuberc Lung Dis; 2012 Feb; 16(2):196-202. PubMed ID: 22236920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rifampicin-monoresistant Mycobacterium tuberculosis disease among children in Cape Town, South Africa.
    Dramowski A; Morsheimer MM; Jordaan AM; Victor TC; Donald PR; Schaaf HS
    Int J Tuberc Lung Dis; 2012 Jan; 16(1):76-81. PubMed ID: 22236850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rifampicin mono-resistance in Mycobacterium tuberculosis in KwaZulu-Natal, South Africa: a significant phenomenon in a high prevalence TB-HIV region.
    Coovadia YM; Mahomed S; Pillay M; Werner L; Mlisana K
    PLoS One; 2013; 8(11):e77712. PubMed ID: 24223122
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rifampicin-Monoresistant Tuberculosis Is Not the Same as Multidrug-Resistant Tuberculosis: a Descriptive Study from Khayelitsha, South Africa.
    Salaam-Dreyer Z; Streicher EM; Sirgel FA; Menardo F; Borrell S; Reinhard M; Doetsch A; Cudahy PGT; Mohr-Holland E; Daniels J; Dippenaar A; Nicol MP; Gagneux S; Warren RM; Cox H
    Antimicrob Agents Chemother; 2021 Oct; 65(11):e0036421. PubMed ID: 34460307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential contribution of HIV during first-line tuberculosis treatment to subsequent rifampicin-monoresistant tuberculosis and acquired tuberculosis drug resistance in South Africa: a retrospective molecular epidemiology study.
    Cox H; Salaam-Dreyer Z; Goig GA; Nicol MP; Menardo F; Dippenaar A; Mohr-Holland E; Daniels J; Cudahy PGT; Borrell S; Reinhard M; Doetsch A; Beisel C; Reuter A; Furin J; Gagneux S; Warren RM
    Lancet Microbe; 2021 Nov; 2(11):e584-e593. PubMed ID: 34766068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rifampin monoresistant tuberculosis and HIV comorbidity in California, 1993-2008: a retrospective cohort study.
    Prach LM; Pascopella L; Barry PM; Flood J; Porco TC; Hopewell PC; Metcalfe JZ
    AIDS; 2013 Oct; 27(16):2615-22. PubMed ID: 23842135
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evolving rifampicin and isoniazid mono-resistance in a high multidrug-resistant and extensively drug-resistant tuberculosis region: a retrospective data analysis.
    Mvelase NR; Balakrishna Y; Lutchminarain K; Mlisana K
    BMJ Open; 2019 Nov; 9(11):e031663. PubMed ID: 31699736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isoniazid-monoresistant tuberculosis is associated with poor treatment outcomes in Durban, South Africa.
    van der Heijden YF; Karim F; Mufamadi G; Zako L; Chinappa T; Shepherd BE; Maruri F; Moosa MS; Sterling TR; Pym AS
    Int J Tuberc Lung Dis; 2017 Jun; 21(6):670-676. PubMed ID: 28482962
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The evolving epidemic of drug-resistant tuberculosis among children in Cape Town, South Africa.
    Seddon JA; Hesseling AC; Marais BJ; Jordaan A; Victor T; Schaaf HS
    Int J Tuberc Lung Dis; 2012 Jul; 16(7):928-33. PubMed ID: 22583610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rifampin-resistant Tuberculosis in the United States, 1998-2014.
    Sharling L; Marks SM; Goodman M; Chorba T; Mase S
    Clin Infect Dis; 2020 Apr; 70(8):1596-1605. PubMed ID: 31233131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk factors for rifampin-monoresistant tuberculosis: A case-control study.
    Sandman L; Schluger NW; Davidow AL; Bonk S
    Am J Respir Crit Care Med; 1999 Feb; 159(2):468-72. PubMed ID: 9927359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isoniazid Monoresistance and Rate of Culture Conversion among Patients in the State of Georgia with Confirmed Tuberculosis, 2009-2014.
    Salindri AD; Sales RF; DiMiceli L; Schechter MC; Kempker RR; Magee MJ
    Ann Am Thorac Soc; 2018 Mar; 15(3):331-340. PubMed ID: 29131662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of Xpert MTB/RIF with other nucleic acid technologies for diagnosing pulmonary tuberculosis in a high HIV prevalence setting: a prospective study.
    Scott LE; McCarthy K; Gous N; Nduna M; Van Rie A; Sanne I; Venter WF; Duse A; Stevens W
    PLoS Med; 2011 Jul; 8(7):e1001061. PubMed ID: 21814495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Xpert
    Kohli M; Schiller I; Dendukuri N; Dheda K; Denkinger CM; Schumacher SG; Steingart KR
    Cochrane Database Syst Rev; 2018 Aug; 8(8):CD012768. PubMed ID: 30148542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Microbiological investigation for tuberculosis among HIV-infected children in Soweto, South Africa.
    Fairlie L; Muchiri E; Beylis CN; Meyers T; Moultrie H
    Int J Tuberc Lung Dis; 2014 Jun; 18(6):676-81. PubMed ID: 24903938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spoligotype-based comparative population structure analysis of multidrug-resistant and isoniazid-monoresistant Mycobacterium tuberculosis complex clinical isolates in Poland.
    Jagielski T; Augustynowicz-Kopec E; Zozio T; Rastogi N; Zwolska Z
    J Clin Microbiol; 2010 Nov; 48(11):3899-909. PubMed ID: 20810763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Xpert MTB/RIF for TB diagnosis in a primary care clinic with high TB and HIV prevalence in South Africa: a pragmatic randomised trial.
    Cox HS; Mbhele S; Mohess N; Whitelaw A; Muller O; Zemanay W; Little F; Azevedo V; Simpson J; Boehme CC; Nicol MP
    PLoS Med; 2014 Nov; 11(11):e1001760. PubMed ID: 25423041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Culture-confirmed childhood tuberculosis in Cape Town, South Africa: a review of 596 cases.
    Schaaf HS; Marais BJ; Whitelaw A; Hesseling AC; Eley B; Hussey GD; Donald PR
    BMC Infect Dis; 2007 Nov; 7():140. PubMed ID: 18047651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes among tuberculosis patients with isoniazid resistance in Georgia, 2007-2009.
    Gegia M; Cohen T; Kalandadze I; Vashakidze L; Furin J
    Int J Tuberc Lung Dis; 2012 Jun; 16(6):812-6. PubMed ID: 22507372
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic accuracy and usefulness of the Genotype MTBDRplus assay in diagnosing multidrug-resistant tuberculosis in Cameroon? a cross-sectional study.
    Abanda NN; Djieugoué JY; Lim E; Pefura-Yone EW; Mbacham WF; Vernet G; Penlap VM; Eyangoh SI; Taylor DW; Leke RGF
    BMC Infect Dis; 2017 May; 17(1):379. PubMed ID: 28569148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.